Aileron-logo.png
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
15 mai 2024 17h13 HE | Aileron Therapeutics, Inc.
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated ...
Aileron-logo.png
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
06 mai 2024 16h05 HE | Aileron Therapeutics, Inc.
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
Aileron-logo.png
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
03 mai 2024 16h05 HE | Aileron Therapeutics, Inc.
AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
Aileron-logo.png
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
01 mai 2024 08h45 HE | Aileron Therapeutics, Inc.
AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
Aileron-logo.png
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
01 mai 2024 08h30 HE | Aileron Therapeutics, Inc.
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a...
Aileron-logo.png
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
15 avr. 2024 17h20 HE | Aileron Therapeutics, Inc.
Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of...
Aileron-logo.png
Aileron Therapeutics Announces CEO Transition
12 mars 2024 08h00 HE | Aileron Therapeutics, Inc.
Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class...
Aileron-logo.png
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event
15 févr. 2024 16h05 HE | Aileron Therapeutics, Inc.
WALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
Aileron-logo.png
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024
01 févr. 2024 16h30 HE | Aileron Therapeutics, Inc.
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address...
Aileron-logo.png
Aileron Therapeutics Announces Termination of Phase 1b Breast Cancer Chemoprotection Trial and Exploration of Strategic Alternatives
21 févr. 2023 08h30 HE | Aileron Therapeutics, Inc.
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with...